Telix, Regeneron (REGN), and NAYA Therapeutics are turning radiopharmaceuticals into one of Wall Street’s more serious new growth stories—while quietly building the kind of supply-chain moats that would make an oil baron blush.
Telix and Regeneron: A $2 Billion Bet on “Hot” Antibodies
Regeneron’s move into radiopharmaceuticals via its collaboration with Telix carries headline numbers designed to wake up even the most jaded healthcare PMs: up to roughly $2.1 billion in potential milestones tied to a multi-program alliance in precision oncology. The two companies plan to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost- and profit-sharing structure, effectively turning both sides into co-owners of a future pipeline rather than mere counterparties on a licensing deal.
The partnership marries Regeneron’s biologics engine—including its VelocImmune-derived antibody platforms and expanding portfolio of oncology targets—with Telix’s radiopharmaceutical development expertise, manufacturing network, and global supply-chain infrastructure. Multiple solid tumor indications are on the table, and the companies intend to pair therapeutic candidates with companion radio-diagnostics to support patient selection and treatment-response monitoring—an increasingly non-negotiable feature in precision oncology.
Why Radiopharma Has Wall Street’s Attention
Radiopharmaceuticals have shifted from niche curiosity to one of oncology’s more coveted growth corridors, helped along by recent regulatory approvals, surging demand for therapeutic isotopes, and the success of PSMA-targeted agents in prostate cancer. Their appeal is straightforward: use a biologic or small-molecule “homing device” to deliver a radioactive payload directly to tumors, sparing more healthy tissue than traditional chemotherapy and creating a profile that reads like a banker’s dream—high specificity, modular platforms, and strong barriers to entry around manufacturing.
For large-cap pharma, these dynamics have triggered a land grab, with marquee names striking deals to secure platforms, supply, and know-how in radioligand and targeted alpha therapies. Regeneron’s tie-up with Telix fits squarely into this pattern, signaling its intent not to watch the category from the sidelines while peers accumulate assets and long-term optionality in the space.
NAYA Therapeutics: Building a Moat in Astatine-211
While Telix and Regeneron assemble a global platform, NAYA Therapeutics is quietly constructing something more granular—and potentially just as strategic—around the radionuclide astatine-211. The company is advancing NY‑703, a GPC3-targeting At‑211 alpha therapy for hepatocellular carcinoma, supported by a research and manufacturing partnership with Alpha Nuclide that will supply At‑211 from a TR‑Alpha cyclotron-equipped production center near Shanghai as it moves into investigator-initiated trials in China.
To turn that scientific thesis into a viable business, NAYA has also aligned with Atley Solutions, whose automated Atley C100 module is designed to purify, conjugate, and prepare therapeutic doses of At‑211 in close proximity to outpatient treatment centers—effectively pushing manufacturing to the network edge where half-lives become a logistics problem rather than a theoretical constraint. In radiopharma, where isotopes decay on their own timetable, this kind of infrastructure starts to look less like back-office plumbing and more like a durable moat built out of cyclotrons, cassettes, and standard operating procedures.
Governance as a Competitive Asset
NAYA has moved to match its technical ambitions with what it describes as a world-class board of directors, bringing in industry veterans with deep experience in radiopharmaceutical development, commercialization, and healthcare capital markets. For a private or earlier-stage company, this kind of board composition serves not only as governance but as a signaling mechanism to partners and investors that the firm intends to compete in the same league as the better-known radiopharma names now populating institutional portfolios.
In a sector where regulatory navigation, supply-chain contracting, and global trial execution can make or break even strong science, such leadership can compress learning curves and provide a Rolodex that shortens the time from intriguing data to commercial relevance. It also sets the stage for Naya to be seen not simply as a single-asset story in hepatocellular carcinoma, but as a platform company with the governance and infrastructure to support a broader pipeline in targeted alpha therapies.
Here’s Naya’s newly appointment board members:
Ely Benaim, MD, an accomplished physician-executive with over 25 years of experience in oncology drug development and clinical leadership. A pediatric hematologist/oncologist, he has held senior roles at leading biotechnology and pharmaceutical companies, including Amgen, Millennium/Takeda, Novocure, and SonALAsense. Dr. Benaim currently serves as Chief Medical Officer of Henlius Fosun USA, where he leads U.S. clinical strategy and development initiatives. His career is distinguished by bringing multiple innovative cancer treatments from early clinical trials to FDA approval, improving outcomes for patients worldwide.
Margarita Chavez, JD, a seasoned biopharmaceutical executive with over 25 years of dealmaking experience in the healthcare industry, including in biotech licensing, IPOs, and acquisitions. Margarita currently serves on the boards of Aligos Therapeutics and chairs the Strategy Committee, Newron Pharmaceuticals and chairs the BD Committee, and Xylo Bio as Board Chair. She is also Managing Partner of Ilustrada Group, a biotech advisory. Margarita served as Managing Director at AbbVie Ventures and was responsible for investments in Morphic Therapeutics (acquired by Lilly for $3.2Bn), Alector Therapeutics, Jnana Therapeutics (acquired by Otsuka for $1.1Bn), and Accent Therapeutics, among others. As a Director on the Licensing & Acquisitions team of Abbott/AbbVie, Margarita was involved in the in-licensing of Oralissa, and the acquisitions of Immuven, Solvay, and the Lupron franchise. Early in her career, Margarita practiced as a corporate and securities lawyer, advising clients on mergers, acquisitions, public and private financings at Brobeck, Phleger & Harrison LLP in Silicon Valley.
Anne Lauvergeon, PhD, a leading businesswoman, board member, and political advisor. Anne is the founder and President of ALP (Anne Lauvergeon Partners), an advisory and investment company mostly dedicated to innovation. She has served on over a dozen boards, including American Express, Airbus, Vodafone and TotalEnergies. She was twice named by Time Magazine as one of the 100 most influential people in the world. She previously served as chairman and Chief Executive Officer of global nuclear energy leader AREVA. During her tenure, she initiated the application of nuclear energy to medicine under AREVA Med, which later transformed into radiopharmaceutical leader Orano Med. Some of her previous roles include Partner at Lazard, the world’s largest independent investment bank, President of the French Government’s 2030 Innovation Commission, which oversees €54 billions of planned investment, and Senior Advisor & Deputy Chief-of-Staff to the French President.
Rahul Singhvi, PhD, MBA, a global leader in the life sciences industry. Rahul was previously cofounder & CEO of biomanufacturing company National Resilience, Inc., where he helped raise over $2 Billion. Prior to co-founding Resilience in 2020, Rahul was an Operating Partner at Flagship Pioneering, where he was responsible for founding and operating companies launched from Flagship Labs. Before joining Flagship, Rahul served as the Chief Operating Officer of the vaccine business unit at Takeda Pharmaceutical Co., where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Rahul was President and CEO of Novavax, Inc. and held several positions with Merck & Co in R&D and manufacturing. Rahul graduated as the top ranked chemical engineer from Indian Institute of Technology (IIT), Kanpur and earned both his masters and doctoral degrees in Chemical Engineering from MIT. He earned his MBA from the Wharton School at the University of Pennsylvania where he graduated as a Palmer Scholar. Rahul serves on the Board of Directors for Codexis, and Kairos Pharmaceuticals.
The Emerging Radiopharma Supply Chain Wars
Taken together, Telix/Regeneron and NAYA illustrate how the radiopharma race is evolving beyond “who has the best target” into a contest over who controls the isotope, the manufacturing node, and the last-mile logistics to clinic. Telix brings a global radiopharmaceutical manufacturing and distribution footprint that can support multiple programs across geographies, while Regeneron supplies a pipeline of antibodies and bispecifics hungry for differentiated payloads.markets.
NAYA, by contrast, is carving out a specialized position in At‑211, partnering with cyclotron operators and advanced module manufacturers to de‑risk supply for a radionuclide that many in the field view as highly promising but operationally demanding. For investors, the message is clear: in radiopharma, balance sheets and binding affinities matter, but so do truck routes, time zones, and who owns the keys to the hot lab. On this front, Telix, Regeneron, and Naya are all making the case that their particular slice of the value chain is built to endure.
The Sources
- Telix Pharmaceuticals – Company Homepage
https://telixpharma.comtelixpharma - Telix Pharmaceuticals – LinkedIn Company Profile
https://www.linkedin.com/company/telixpharmalinkedin - Telix Pharmaceuticals – TLX Stock Quote and Overview
https://finance.yahoo.com/quote/TLX/finance.yahoo - Regeneron Pharmaceuticals – Company Homepage
https://www.regeneron.comregeneron - Regeneron Pharmaceuticals – Company Overview (BioCT)
https://bioct.org/member/regeneron-pharmaceuticals/bioct - Regeneron Pharmaceuticals – Wikipedia Company Entry
https://en.wikipedia.org/wiki/Regeneron_Pharmaceuticalswikipedia - NAYA Therapeutics – Company Homepage
https://www.nayatx.comnayatx - NAYA Therapeutics – News & Press Releases
https://www.nayatx.com/newsnayatx - NAYA Therapeutics – Company Overview and Pipeline (Catalyst Investors’ Club)
https://catalyst-ic.com/en/company/69315ff61f6b1ee3cd367865catalyst-ic - NAYA Therapeutics – LinkedIn Company Profile
https://www.linkedin.com/company/naya-therapeuticslinkedin - NAYA Therapeutics Announces World-Class Board of Directors – ACCESS Newswire
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-announces-world-class-board-of-directors-1148490accessnewswire - NAYA Therapeutics to Partner with Atley Solutions to Accelerate the Development and Commercialization of At‑211 Radiopharmaceuticals
https://atley.com/news/naya-therapeutics-to-partner-with-atley-solutions-to-accelerate-the-development-and-commercialization-of-nayas-at-211-radiopharmeceuticalsatley - NAYA Therapeutics Partners With Ionetix to Build a U.S. Production & Supply Network for Astatine‑211 (LinkedIn Post)
https://www.linkedin.com/posts/naya-therapeutics_naya-therapeutics-partners-with-ionetix-to-activity-7364322958313472001-B9Gulinkedin
